ArticlePloS one2025
Short-term real-world outcomes of diabetic macular edema treated with intravitreal faricimab.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Dynamics of Hyper-Reflective Foci and Hard Exudates in Diabetic Macular Edema Treated with Faricimab.Journal of clinical medicine · 2026Article
- Faricimab for Diabetic Macular Edema in Eyes Vitrectomized for Proliferative Diabetic Retinopathy: A 12-Month Retrospective Study.Journal of clinical medicine · 2026Article
- Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore.Ophthalmology and therapy · 2026Article
- First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria.Journal of clinical medicine · 2026Article
- Changes in retinal venous diameter in proliferative diabetic retinopathy patients with diabetic macular edema following faricimab treatment: an observational study.Frontiers in endocrinology · 2026Observational
- Visual Gains with Faricimab vs Aflibercept 8 mg in Naïve Retinovascular Disease: Global Real-World Cases and Literature Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Efficacy and Safety of Faricimab in Diabetic Macular Edema: Real-World Outcomes in Treatment-Naïve and Previously Treated Eyes.Journal of clinical medicine · 2025Article
- Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion.International journal of retina and vitreous · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Faricimab, a new drug for diabetic macular edema (DME), was made available in Japan in 2022. However, few reports have been published about its treatment outcomes in clinical practice. To assess the short-term outcomes of intravitreal faricimab (IVF) in patients with DME, the records of patients with DME receiving IVF therapy between July 2022 and July 2023 at Juntendo University Hospital were retrospectively reviewed. Their best-corrected visual acuities in the logarithm of the minimum angle of resolution units and central macular thicknesses were compared at baseline and one month after the final IVF. Eighteen patients and 22 eyes were included and allocated to the naïve and switched groups: 12 cases (15 eyes) and 6 cases (7 eyes), respectively. The best-corrected visual acuity improved for the naïve group, but no difference was observed for the switched group. In contrast, the central macular thickness improved for both the naïve and switched groups. IVF demonstrated good short-term outcomes for DME, suggesting that it is effective for DME in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.